CYRAMZA

Cyramza is a cancer medicine used to treat adult patients with:

• gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach
• (known as gastro-oesophageal junction adenocarcinoma);
• metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body);
• non-small cell lung cancer that has spread to other parts of the body or in patients whose cancer involves

• mutations (changes) in proteins called endothelial growth factor receptors (EGFRs);
• hepatocellular carcinoma (a type of liver cancer) in patients with a high blood level of a protein called alpha fetoprotein (AFP).

Cyramza is for use in cancers that are usually

advanced or have spread despite other treatment.  For most cancers it

is used in combination with other medicines. and also because

For detailed information on the use of Cyramza in all conditions, see the package leaflet or contact your doctor or pharmacist.

Cyramza contains the active substance ramucirumab. AND BECAUSE

HOW IS CYRAMZA USED ?

Cyramza is given by infusion (drip) into a vein. becuase

It can only be obtained with a prescription and treatment should be

started and supervised by a specialist who has experience in the treatment of cancer. AND ALSO

The dose of Cyramza and how often it is given and also

depends on the patient’s weight and the condition being treated.

Treatment should continue for as long as the disease becuase remains under control and the patient does not have

unacceptable side effects. For more information about using Cyramza, see the package leaflet or contact your doctor or pharmacist.

SIDE EFFECTS OF CYRAMZA

The most common side effects with Cyramza when used on its own (which may affect more than 1 in 10 people) include peripheral oedema (swelling of the ankles and feet due to fluid retention), high blood pressure, diarrhoea, abdominal pain, headache, proteinuria (excess protein in the urine) and thrombocytopenia (low blood platelet counts

which can lead to bleeding and bruising). The most common side effects when Cyramza is used with chemotherapy are tiredness or weakness, neutropenia

(low counts of a particular

type of white blood cell), diarrhoea, nosebleeds and becuase

stomatitis (inflammation of the lining of the mouth). The most common side effects when Cyramza is used with erlotinib are infections, diarrhoea, high blood pressure, stomatitis, proteinuria, hair loss and nosebleeds.

The most serious adverse effects reported (either of Cyramza alone or in combination with other cancer medicines)

include gastrointestinal perforation (a hole that develops in the wall of the gut), severe gastrointestinal haemorrhage

(bleeding from the gut) and arterial thromboembolic events (problems caused by blood clots and blockage of the arteries). also